A Phase 1/2 interventional study of Conditioned Medium and Umbilical Cord Mesenchymal Stem Cells in Ischemic Stroke, sponsored by PT. Prodia Stem Cell Indonesia. Active, not recruiting at 2 sites in Indonesia. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by PT. Prodia Stem Cell Indonesia · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Ischemic Stroke with a site in Indonesia — 3 open to participants now, 4 under way, 1 of them phase 3. Ischemic Stroke · Indonesia.
Among the 10 studies in Ischemic Stroke with a site in Indonesia, this one is the 9th largest by planned enrollment, is the only one that started in 2022, is the only one in phase 1/2, and was the 6th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →3 of the 10 studies in Ischemic Stroke with a site in Indonesia are open now. Recruiting first, the newest first:
Jumraini Tammasse · Sites in Indonesia
Ages 40–75
Boehringer Ingelheim · Sites in Indonesia, Argentina, Australia and 13 more countries
Ages 18+
Jumraini Tammasse · Sites in Indonesia
Ages 30–75
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 25 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 5 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 75 across the 10 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 7 most frequent:
PT. Prodia Stem Cell Indonesia is the lead sponsor of 16 studies on the registry; 7 are open to participants now.
PT. Prodia Stem Cell Indonesia has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
3 of the studies in Ischemic Stroke with a site in Indonesia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07361302Phase 3Boehringer IngelheimA Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | 2027-10-02 |
| NCT07731087Jumraini TammasseMSC Secretome Therapy for Cognitive Recovery After Subacute Ischemic Stroke | 2026-11 |
| NCT07874269Jumraini TammasseMSC Secretome and rTMS for Motor Recovery After Subacute Ischemic Stroke | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Ischemic Stroke with a site in Indonesia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine the effectiveness of a combination of intranasal conditioned medium (CM) with intraparenchymal umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in acute stroke patients to induce neurogenesis.
This study has 3 arms namely CM and UC-MSCs treatment, UC-MSCs treatment only, and control. The investigator hypothesized that group of CM and UC-MSCs combination is the optimal treatment to induce neurogenesis in stroke patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intranasal of 3 cc of conditioned medium each, for 3 days in a row and Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
Biological: Conditioned Medium · Biological: Umbilical Cord Mesenchymal Stem Cells
Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
Biological: Umbilical Cord Mesenchymal Stem Cells
Neurologic and Neutrophic Drugs
Procedure: Neurologic and Neutrophic Drugs
Intranasal of 3 cc of conditioned medium each, for 3 days in a row
Also known as: Secretome
Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
Also known as: Mesenchymal stromal cells
Such as clopidogrel, piracetam, citicoline
Change from baseline Brain-Derived Neutrophic Factor at one month, 3 months and 6 months after transplantation
Venous blood collection
Time frame: Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment
Change from baseline Vascular endothelial growth factor at one month, 3 months and 6 months after transplantation
Venous blood collection
Time frame: Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment
Change baseline Magnetic Resonance Imaging at 6 month after transplantation
To observe the brain development (neurogenesis)
Time frame: Before treatment, 6 month after transplantation
The National Institute of Health Stroke Scale (NIHSS) Scoring
The NIH Stroke Scale (NIHSS) is a 15-item scale that is a well-validated and prognostically important measure of stroke-related neurologic deficits in research and clinical care
Time frame: Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment
modified Rankin Scale (mRS)
The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke
Time frame: Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment
Started May 2022 (actual). Primary completion is estimated for Mar 2026, 46 months after the start.
Of 27 phase 1/2 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 46 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solizmestrocel
PT. Prodia Stem Cell Indonesia